Jusprin 81 mg tablet banned

After being banned in the United Arab Emirates for failing to meet health standards, Bahrain has pulled the pharmaceutical brand Julphar Aspirin from its shelves, Health Ministry said last night in a press statement. Jusprin 81 mg tablet, manufactured by Gulf Pharmaceutical Industries (Julphar), is a drug prescribed to treat or prevent heart attacks.

Julphar, according to the Ministry, has failed to satisfy the guidelines set by the Gulf Cooperation Council (GCC) for pharmaceuticals. Last week, Health authorities in the UAE withdrew the lowdose aspirin tablet also used to treat pain and reduce fever or inflammation. ‘Aspirin’ from another company is currently available at all health centres and hospitals under the ministry, the statement confirmed. 

Return Jusprin tablets

The Ministry of Health has called on all to return Jusprin 81 mg tablets from Julphar to the health centres or hospitals from where it was supplied to receive the same quantity of the medicine from another company.  The ministry said it has directed the supplier to withdraw the drug and urged health professionals and pharmacists to stop prescribing Jusprin 81 mg tablets and return the stocks to the supplier.

Julphar confirms recall

Meanwhile, Julphar, one of the largest pharmaceutical manufacturers in the Middle East, has issued a statement reinforcing its commitment to quality following the recall by the UAE Ministry of Health and Prevention (MoHAP). Jerome Carle, General Manager of Julphar, said: “We can confirm that low-dose aspirin medicine, Jusprin 81mg, has been recalled by MoHAP due to an issue over its stability.” 

“The global nature of our business requires that the Julphar system has the highest standards and processes to ensure consistent quality across our entire value chain – from the supply of materials through to manufacturing and approval by the leading authorities in the world. “Our consumers deserve safe, effective and quality products, and across the Julphar system, we work hard to meet the highest standards of safety and quality.

“We follow stringent procedures designed to ensure the safety and quality of each of our products. Our scientific teams are working hand in hand with MoHAP and we are following their recommendations to the letter to ensure a quick resolution.”